PDF(Pubmed)
Abstract：
UNASSIGNED: Given the considerable discrepancies in the evidence concerning the efficacy of statins in ameliorating cognitive impairments in pediatric patients with Neurofibromatosis Type 1 (NF-1), this study conducts a systematic review and meta-analysis to consolidate existing evidence to evaluate the efficacy of statins on cognitive impairments in children with NF-1.
UNASSIGNED: This study adhered to the PRISMA statement, and the research protocol was pre-registered on PROSPERO (#CRD: 42022369072). Comprehensive searches of databases including PubMed, Embase, and the Cochrane Library were performed up to March 31, 2023 to identify randomized controlled trials (RCTs) investigating the effects of statins on cognitive impairments in children with NF-1. Statistical analyses were conducted using Review Manager 5.4.1. A fixed- or random-effects model was employed according to the I2 statistic. As all data were continuous, MD [95% CI] was used as the pooled estimate.
UNASSIGNED: The final analysis included five RCTs with a total of 364 patients. The meta-analysis indicated that aside from a statistically significant improvement in internalizing problems (MD [95%CI] = 3.61[0.11, 7.10], p = 0.04), Object assembly Test (MD [95%CI] = 0.53[0.12, 0.93], p = 0.01), Cancellation Test (MD [95%CI] = 3.61[0.11, 7.10], p < 0.0001), statins did not exhibit significant efficacy in improving other cognitive aspects in children with NF-1 (p > 0.05). An additional descriptive analysis on indices that cannot be meta-analyzed revealed considerable inconsistency in the therapeutic effect of statins across different studies.
UNASSIGNED: Current evidence suggests that statins may not be effective for cognitive performance in children with NF-1.
UNASSIGNED: This study adhered to the PRISMA statement, and the research protocol was pre-registered on PROSPERO (#CRD: 42022369072). Comprehensive searches of databases including PubMed, Embase, and the Cochrane Library were performed up to March 31, 2023 to identify randomized controlled trials (RCTs) investigating the effects of statins on cognitive impairments in children with NF-1. Statistical analyses were conducted using Review Manager 5.4.1. A fixed- or random-effects model was employed according to the I2 statistic. As all data were continuous, MD [95% CI] was used as the pooled estimate.
UNASSIGNED: The final analysis included five RCTs with a total of 364 patients. The meta-analysis indicated that aside from a statistically significant improvement in internalizing problems (MD [95%CI] = 3.61[0.11, 7.10], p = 0.04), Object assembly Test (MD [95%CI] = 0.53[0.12, 0.93], p = 0.01), Cancellation Test (MD [95%CI] = 3.61[0.11, 7.10], p < 0.0001), statins did not exhibit significant efficacy in improving other cognitive aspects in children with NF-1 (p > 0.05). An additional descriptive analysis on indices that cannot be meta-analyzed revealed considerable inconsistency in the therapeutic effect of statins across different studies.
UNASSIGNED: Current evidence suggests that statins may not be effective for cognitive performance in children with NF-1.
摘要：
■鉴于关于他汀类药物改善1型神经纤维瘤病（NF-1）儿科患者认知障碍的有效性的证据存在很大差异，本研究进行了系统评价和荟萃分析,以巩固现有证据,评估他汀类药物对NF-1患儿认知障碍的疗效.
■这项研究坚持PRISMA声明，研究方案在PROSPERO上预先注册(#CRD:42022369072)。全面搜索数据库，包括PubMed，Embase,和Cochrane图书馆进行到2023年3月31日,以确定随机对照试验(RCT),调查他汀类药物对NF-1患儿认知障碍的影响.使用ReviewManager5.4.1进行统计分析。根据I2统计量采用固定或随机效应模型。由于所有数据都是连续的，MD[95%CI]用作汇总估计值。
■最终分析包括五个RCT，总共364名患者。荟萃分析表明，除了内在化问题的统计学显着改善（MD[95CI]=3.61[0.11，7.10]，p=0.04),对象组件测试(MD[95CI]=0.53[0.12,0.93],p=0.01),取消测试（MD[95CI]=3.61[0.11，7.10]，p<0.0001),他汀类药物在改善NF-1患儿的其他认知方面没有显著疗效(p>0.05)。对无法进行荟萃分析的指标的另一项描述性分析显示，在不同研究中，他汀类药物的治疗效果存在相当大的不一致。
■目前的证据表明，他汀类药物可能对NF-1患儿的认知能力无效。
■这项研究坚持PRISMA声明，研究方案在PROSPERO上预先注册(#CRD:42022369072)。全面搜索数据库，包括PubMed，Embase,和Cochrane图书馆进行到2023年3月31日,以确定随机对照试验(RCT),调查他汀类药物对NF-1患儿认知障碍的影响.使用ReviewManager5.4.1进行统计分析。根据I2统计量采用固定或随机效应模型。由于所有数据都是连续的，MD[95%CI]用作汇总估计值。
■最终分析包括五个RCT，总共364名患者。荟萃分析表明，除了内在化问题的统计学显着改善（MD[95CI]=3.61[0.11，7.10]，p=0.04),对象组件测试(MD[95CI]=0.53[0.12,0.93],p=0.01),取消测试（MD[95CI]=3.61[0.11，7.10]，p<0.0001),他汀类药物在改善NF-1患儿的其他认知方面没有显著疗效(p>0.05)。对无法进行荟萃分析的指标的另一项描述性分析显示，在不同研究中，他汀类药物的治疗效果存在相当大的不一致。
■目前的证据表明，他汀类药物可能对NF-1患儿的认知能力无效。
